G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss.
G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss.
复制标题
DOI：
10.3389/fnmol.2022.1028125
复制
发表时间：
2022
影响因子：
4.8
通讯作者：
Chai, Renjie
中科院分区：
文献类型：
--
作者：
Ma, Xiangyu;Guo, Jiamin;Fu, Yaoyang;Shen, Cangsong;Jiang, Pei;Zhang, Yuan;Zhang, Lei;Yu, Yafeng;Fan, Jiangang;Chai, Renjie
由不同因素引起的听力损失相关疾病在世界范围内的发病率呈逐年上升趋势。然而，目前患者的听力损失并没有得到有效的改善。因此，迫切需要采取新的治疗措施和治疗技术来帮助提高听力损失的治疗效果。G蛋白偶联受体（gpcr）作为重要的细胞表面受体，可以广泛参与不同的生理和病理过程，特别是在许多疾病的发生中发挥重要作用，是有希望的治疗靶点。然而，市场上还没有发现针对耳蜗gpcr的特异性药物。有趣的是，近年来的许多研究表明，gpcr可以参与耳蜗中与听力损失相关的各种致病过程，包括遗传、噪声、耳毒性药物、耳蜗结构等。本文综述了耳蜗中已知的53种GPCR基因的功能及其与听力损失的关系，重点介绍了冷冻电镜、人工智能、GPCR药物筛选、基因治疗载体、CRISPR编辑技术等耳蜗研究新技术的最新进展，并深入探讨了基于GPCR的新型耳蜗听力损失药物开发和基因治疗的未来方向。总之，本综述旨在促进该领域的基础和（前）临床研究，并为新兴的基于gpcr的耳蜗治疗提供有益的帮助。
The prevalence of hearing loss-related diseases caused by different factors is increasing worldwide year by year. Currently, however, the patient’s hearing loss has not been effectively improved. Therefore, there is an urgent need to adopt new treatment measures and treatment techniques to help improve the therapeutic effect of hearing loss. G protein-coupled receptors (GPCRs), as crucial cell surface receptors, can widely participate in different physiological and pathological processes, particularly play an essential role in many disease occurrences and be served as promising therapeutic targets. However, no specific drugs on the market have been found to target the GPCRs of the cochlea. Interestingly, many recent studies have demonstrated that GPCRs can participate in various pathogenic process related to hearing loss in the cochlea including heredity, noise, ototoxic drugs, cochlear structure, and so on. In this review, we comprehensively summarize the functions of 53 GPCRs known in the cochlea and their relationships with hearing loss, and highlight the recent advances of new techniques used in cochlear study including cryo-EM, AI, GPCR drug screening, gene therapy vectors, and CRISPR editing technology, as well as discuss in depth the future direction of novel GPCR-based drug development and gene therapy for cochlear hearing loss. Collectively, this review is to facilitate basic and (pre-) clinical research in this area, and provide beneficial help for emerging GPCR-based cochlear therapies.
登录
查看更多内容
DOI：
10.1038/mt.2015.220
发表时间：
2016-03
期刊：
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子：
--
作者：
Bakondi B;Lv W;Lu B;Jones MK;Tsai Y;Kim KJ;Levy R;Akhtar AA;Breunig JJ;Svendsen CN;Wang S
通讯作者：
Wang S
DOI：
10.1016/j.pnpbp.2018.10.005
发表时间：
2019-03-08
影响因子：
5.6
作者：
Aminyavari, Samaneh;Zahmatkesh, Maryam;Zarrindast, Mohammad-Reza
通讯作者：
Zarrindast, Mohammad-Reza
DOI：
10.1016/s0169-328x(02)00662-9
发表时间：
2003-02-20
期刊：
MOLECULAR BRAIN RESEARCH
影响因子：
--
作者：
Calver, AR;Michalovich, D;Pangalos, MN
通讯作者：
Pangalos, MN
影响因子：
7.7
作者：
Babola, Travis A.;Kersbergen, Calvin J.;Bergles, Dwight E.
通讯作者：
Bergles, Dwight E.
影响因子：
2.8
作者：
AitRaise, Imane;Amalou, Ghita;Barakat, Adbelhamid
通讯作者：
Barakat, Adbelhamid